Evidence map›Paper›PMID 26284363›Full record

ArticlePloS one2015

Amniotic Membrane Modifies the Genetic Program Induced by TGFß, Stimulating Keratinocyte Proliferation and Migration in Chronic Wounds.

Antonia Alcaraz, Anna Mrowiec, Carmen Luisa Insausti, Ángel Bernabé-García, Eva María García-Vizcaíno, María Concepción López-Martínez, Asunción Monfort, Ander Izeta, José María Moraleda, Gregorio Castellanos and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 44 citations in OpenAlex.

  1. An open-label trial of cryopreserved human umbilical cord in the treatment of complex diabetic foot ulcers complicated by osteomyelitis.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2019
    Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Perinatal derivatives: How to best characterize their multimodal functionsFrontiers in bioengineering and biotechnology · 2022
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Antonia AlcarazOncología Molecular y TGFß, Unidad de Investigación, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Anna MrowiecOncología Molecular y TGFß, Unidad de Investigación, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Carmen Luisa InsaustiUnidad de Terapia Celular, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Ángel Bernabé-GarcíaOncología Molecular y TGFß, Unidad de Investigación, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Eva María García-VizcaínoOncología Molecular y TGFß, Unidad de Investigación, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
María Concepción López-MartínezOncología Molecular y TGFß, Unidad de Investigación, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Asunción MonfortInstituto Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain.
Ander IzetaInstituto Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain.
José María MoraledaUnidad de Terapia Celular, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Gregorio CastellanosServicio de Cirugía, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Francisco José NicolásOncología Molecular y TGFß, Unidad de Investigación, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Hospital Universitario Virgen de la Arrixaca · ESBiogipuzkoa Health Research Institute · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPost-traumatic large-surface or deep wounds often cannot progress to reepithelialisation because they become irresponsive in the inflammatory stage, so intervention is necessary to provide the final sealing epidermis. Previously we have shown that Amniotic Membrane (AM) induced a robust epithelialisation in deep traumatic wounds. METHODS AND

findingsTo better understand this phenomenon, we used keratinocytes to investigate the effect of AM on chronic wounds. Using keratinocytes, we saw that AM treatment is able to exert an attenuating effect upon Smad2 and Smad3 TGFß-induced phosphorylation while triggering the activation of several MAPK signalling pathways, including ERK and JNK1, 2. This also has a consequence for TGFß-induced regulation on cell cycle control key players CDK1A (p21) and CDK2B (p15). The study of a wider set of TGFß regulated genes showed that the effect of AM was not wide but very concrete for some genes. TGFß exerted a powerful cell cycle arrest; the presence of AM however prevented TGFß-induced cell cycle arrest. Moreover, AM induced a powerful cell migration response that correlates well with the expression of c-Jun protein at the border of the healing assay. Consistently, the treatment with AM of human chronic wounds induced a robust expression of c-Jun at the wound border.

conclusionsThe effect of AM on the modulation of TGFß responses in keratinocytes that favours proliferation together with AM-induced keratinocyte migration is the perfect match that allows chronic wounds to move on from their non-healing state and progress into epithelialization. Our results may explain why the application of AM on chronic wounds is able to promote epithelialisation.

Indexed as

AmnionAnimalsCell CycleCell ProliferationCells, CulturedEpithelial CellsHumansKeratinocytesLungMAP Kinase Signaling SystemMinkPhosphorylationProto-Oncogene Proteins c-junRe-EpithelializationSmad2 ProteinTransforming Growth Factor betaProto-Oncogene Proteins c-junSmad2 ProteinSMAD2 protein, humanTransforming Growth Factor beta

Identifiers

PMID26284363
PMCPMC4540284
OpenAlexW1845480752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.